Another biosimilar of one of the world’s best-selling oncology drugs, Avastin (bevacizumab), has been approved by the US Food and Drug Administration (FDA).
Pfizer’s (NYSE: PFE) Zirabev (bevacizumab-bvzr), a copy of Roche’s (ROG: SIX) original biologic, received approval for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.
The first Avastin biosmilar, Mvasi (bevacizumab-awwb), from Amgen (Nasdaq: AMGN) and Allergan (NYSE: AGN), was approved by the FDA in September 2017, but it has still not been launched.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze